RecruitingPHASE2, PHASE3NCT05139017
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Zilovertamab vedotin(biological)
- Enrollment
- 290 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175), Glendale, Arizona, United States
- Beverly Hills Cancer Center ( Site 0184), Beverly Hills, California, United States
- Bass Medical Group ( Site 0166), Walnut Creek, California, United States
- Innovative Clinical Research Institute ( Site 0122), Whittier, California, United States
- Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton, Florida, United States
- Clermont Oncology Center ( Site 0174), Clermont, Florida, United States
- BRP-Hialeah Hospital ( Site 0182), Hialeah, Florida, United States
- Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood, Kentucky, United States
- University of Kentucky Chandler Medical Center ( Site 0158), Lexington, Kentucky, United States
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133), Louisville, Kentucky, United States
- University of Maryland ( Site 0123), Baltimore, Maryland, United States
- Dana-Farber Cancer Institute-Lymphoma ( Site 0111), Boston, Massachusetts, United States
- University of Massachusetts Medical School ( Site 0119), Worcester, Massachusetts, United States
- Corewell Health ( Site 0162), Grand Rapids, Michigan, United States
- St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings, Montana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05139017 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.